Lijun International Pharmaceutical (Holding) Co., Ltd. reported that its Enerxin Capsules, an antiviral drug, was recognized by the State Key Laboratory of Virology for effective restraint of the growth of influenza A (H1N1). The effects of the drug were similar to Tamiflu. Enerxin was developed by a subsidiary of Lijun, Shijiazhuang No.4 Pharmaceutical Co., Ltd. More details...

Stock Symbol: (HKEX: 2005)